Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was ...

The financial markets responded immediately, with BioNTech shares declining as much as 5% in pre-market trading. This partnership has historically formed the cornerstone of BioNTech's commercial ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 ...

A BioNTech spokesperson told Reuters that the two companies continue to have a “close and strong collaboration.” ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

--Pfizer is trying to sell its stake in BioNTech SE, Bloomberg reported, citing people familiar with the matter. --Pfizer is offering 4.55 million American depositary receipts for $108 to $111.70 a ...

Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies ...

There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be ...